ANTIBODY-MEDIATED REJECTION OF KIDNEY GRAFTS: COMPARISON OF STANDARD THERAPY AND THERAPY WITH ADDITION OF BORTEZOMIB AND/ OR RITUXIMAB

被引：0
|
作者：
Oblak, Teja [1 ]
Lindic, Jelka [1 ]
Kveder, Radoslav [1 ]
Rigler, Andreja Ales [1 ]
Skoberne, Andrej [1 ]
Haler, Zeljka Veceric [1 ]
Borstnar, Spela [1 ]
Avgustin, Nusa [1 ]
Gubensek, Jakob [1 ]
Ponikvar, Rafael [1 ]
Mlinsek, Gregor [1 ]
Ferluga, Dusan [2 ]
Kojc, Nika [2 ]
Kovac, Damjan [1 ]
机构：
[1] Univ Med Ctr Ljubljana, Dept Nephrol, Ljubljana, Slovenia
[2] Univ Ljubljana, Inst Pathol, Med Fac, Ljubljana, Slovenia
来源：
TRANSPLANT INTERNATIONAL | 2017年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
MP059
引用
收藏
页码：386 / 386
页数：1
相关论文
共 50 条
  • [41] Efficacy of Bortezomib as an Adjunctive Therapy for Refractory Chronic Active Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience
    Larpparisuth, Nuttasith
    Skulratanasak, Peenida
    Premasathian, Nalinee
    Vongwiwatana, Attapong
    TRANSPLANTATION PROCEEDINGS, 2019, 51 (10) : 3293 - 3296
  • [42] Bortezomib Therapy for Antibody-Mediated Acute Rejection: Effect on Graft Function and HLA Donor-Specific Antibody Level
    Morales-Buenrostro, Luis E.
    Leyva, Sergio A.
    Marino-Vazquez, Lluvia A.
    Reyes, Jorge A.
    Uribe-Uribe, Norma O.
    Vega-Vega, Olynka
    Alberu, Josefina
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 165 - 165
  • [43] Protective immunity and use of bortezomib for antibody-mediated rejection in a pediatric kidney transplant recipient
    Claes, Donna J.
    Yin, Hong
    Goebel, Jens
    PEDIATRIC TRANSPLANTATION, 2014, 18 (04) : E100 - E105
  • [44] Effectiveness of Rituximab and Intravenous Immunoglobulin Therapy in Renal Transplant Recipients with Chronic Active Antibody-Mediated Rejection
    Hong, Y. A.
    Kim, H. G.
    Choi, S. R.
    Sun, I. O.
    Park, H. S.
    Chung, B. H.
    Choi, B. S.
    Park, C. W.
    Kim, Y. S.
    Yang, C. W.
    TRANSPLANTATION PROCEEDINGS, 2012, 44 (01) : 182 - 184
  • [45] Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study
    Bachelet, Thomas
    Nodimar, Celine
    Taupin, Jean-Luc
    Lepreux, Sebastien
    Moreau, Karine
    Morel, Delphine
    Guidicelli, Gwendaline
    Couzi, Lionel
    Merville, Pierre
    CLINICAL TRANSPLANTATION, 2015, 29 (05) : 439 - 446
  • [46] SECOND-LINE THERAPY AFTER STANDARD OF CARE IN ANTIBODY-MEDIATED REJECTION: A PROSPECTIVE STUDY
    Viglietti, Denis
    Loupy, Alexandre
    Aubert, Olivier
    Legendre, Christophe
    Glotz, Denis
    Lefaucheur, Carmen
    TRANSPLANT INTERNATIONAL, 2017, 30 : 246 - 246
  • [47] Second-Line Therapy After Standard of Care in Antibody-Mediated Rejection: A Prospective Study
    Viglietti, D.
    Loupy, A.
    Aubert, O.
    Pillebout, E.
    Legendre, C.
    Glotz, D.
    Lefaucheur, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 533 - 533
  • [48] Rituximab for Antibody-Mediated Rejection, Less May Be More
    Mulley, William R.
    Kanellis, John
    TRANSPLANTATION, 2009, 88 (01) : 142 - 143
  • [49] The Addition of Bortezomib to a Rituximab Based Antibody Mediated Rejection Treatment Protocol in Lung Transplant.
    Galle, M.
    Stracener, P.
    Warrior, K.
    Lyons, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 991 - 991
  • [50] Proteasome inhibitor-based therapy for antibody-mediated rejection
    Walsh, R. Carlin
    Alloway, Rita R.
    Girnita, Alin L.
    Woodle, E. Steve
    KIDNEY INTERNATIONAL, 2012, 81 (11) : 1067 - 1074
12345